Biomedical Excellence for Safer Transfusion
A A A

Applications open now through 20 June 2022

The Biomedical Excellence for Safer Transfusion (BEST) Collaborative is an international research organization whose objective is to improve the safety of transfusion and cell therapy and related services through standardization of analytic techniques, development of new procedures and execution of clinical trials in hemotherapy and cell therapy. More than 150 scientific publications have resulted from the Collaborative’s work.

Every 4 years, BEST elects a new President, currently Dr. Ziggy Szczepiorkowski, and renews its Board of Directors and scientific membership.

BEST is now looking for new talent to provide continued scientific vigor and fresh ideas. Members are expected to actively participate in BEST studies, contribute ideas for new ones, and participate in BEST meetings. Projects and studies are managed by individual members through one of our four teams:

  • Cellular Therapy
    Current Team Leads: Dave McKenna, MD; David Stroncek, MD
  • Clinical Transfusion Safety
    Current Team Leads: Mark Fung, MD, PhD; Meghan Delaney, DO
  • Conventional Components
    Current Team Leads: Dana Devine, PhD; Rebecca Cardigan, PhD
  • Donor Studies
    Current Team Leads: Marc Germain, MD; Ralph Vassallo, MD

Meetings are held twice per year, generally alternating between a North American venue in autumn and a European venue in spring. The meetings, which are highly interactive, last a day and a half to 2 days, and are always lively and stimulating. Members receive a stipend to assist with travel expenses.

Applications with a letter of interest and CV may be submitted via the BEST Web Site,  HERE

Applications will be accepted through June 20, 2022. Decisions will be announced by September 2022, with the first meeting of the refreshed membership to be held Spring 2023.